Foundation for Angelman Syndrome Therapeutics (FAST)

FAST is the leading patient advocacy organization working to cure Angelman syndrome. As the largest non-governmental funder of Angelman syndrome research in the world, our goal is to drive forward transformative research and development programs as quickly as possible for those living with Angelman syndrome — regardless of age or genotype. Angelman syndrome (AS) is a rare neurogenetic disorder that affects about one in 15,000 people, or approximately 500,000 individuals worldwide. Some say it could be as frequent as one in 8,000 people, or over 1,000,000 individuals worldwide. Children and adults with AS typically have balance issues, motor impairments and can have debilitating seizures. Disruptive sleep is often a serious challenge. Some never walk. Most do not speak. Individuals with AS have a normal life expectancy, but require continuous care and are unable to live independently. This is life today for people living with Angelman syndrome. But it won’t be for long. Scientists believe that AS is now the neurogenetic disorder with the greatest potential to be cured. FAST is the reason why, and the force making it happen.